PTX-367

in Gorlin Syndrome

Client: Palvella Therapeutics

DESCRIPTION

Gorlin Syndrome is a rare genetic disease that causes the cell membrane receptor PTCH1 to stop working. PTCH1 is then unable to suppress the SMO receptor, causing activation of the GLI family of proteins. Through a complex cascade, GLI causes production of mTOR, which is implicated in the formation of basal cell carcinoma.

Palvella has developed PTX-367, a novel formulation of the drug rapamycin. PTX-367 penetrates the skin, targeting tumor cells and inactivating the mTOR proteins, with the goal of inhibiting downstream activity, including cell proliferation and tumor formation.

See also

UroAmplitude

CRISPR-Cas9

OxaliTex

 
 

Our pride and reputation are in everything we deliver.

Visit our process page to see how our award winning animations get created.